Financial Performance
5Y price score: 81
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 152.4%
%
ㅤ
By default your notes are visible only to you.
184.6
52-week range
281.0
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
1.7 %
Dividend Yield TTM
2.1 %
Market cap $
$ 615,874
Price / Earnings TTM
38.7
Price / Book TTM
7.4
PEG TTM
0.4
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
35.7 %
72.9 %
152.4 %
Free cash flow per share growth
(59.7) %
7.3 %
44.2 %
Earnings per share growth
(96) %
100.2 %
101.3 %
Founded: 1,886
Employees: 138,100
Business Summary:
Q&A
Contribute
By providing well-researched and detailed answer you increase your chance of becoming Top Contributor. TopFunds is free for all top contributors. Learn more
Latest Earnings Call Takeaways
2026 Q3 (Oct 13, 2026)
1) Strategic Focus and Leadership - Johnson & Johnson (JNJ) reported strong Q3 2026 results, with operational sales growth of 6%, exceeding analyst expectations. - The company is focusing on six strategic areas: oncology, immunology, neuroscience, cardiovascular surgery, ambition, and MedTech. - JNJ aims to achieve double-digit growth by the end of the decade, supported by a robust product pipeline and recent acquisitions, including Firefly Bio. - The company is on track to exceed $100 billion in annual revenue for the first time.
2) Financial Performance and Segment Results - Q3 2026 worldwide sales reached $25.4 billion, a 6% increase YoY, with U.S. growth at 9.1%. - Net earnings were $210 million, with diluted EPS of $0.09, significantly impacted by litigation expenses and acquisition costs. - Adjusted net earnings were $6.3 billion, with adjusted diluted EPS of $2.59, reflecting a 6.8% decrease YoY. - Innovative Medicine sales grew 7.9% to $16.8 billion, driven by strong performances in oncology and immunology.
3) Challenges and Headwinds - The MedTech segment experienced slower growth at 2.5%, primarily due to challenges in international markets and specific product lines like Abiomed. - Ongoing litigation related to talc products resulted in significant expenses, impacting overall earnings. - Competitive pressures in the MedTech space, particularly in Asia-Pacific, and the effects of geopolitical tensions in the Middle East have created additional headwinds.
4) Operational and Product Plans - JNJ is advancing its oncology pipeline, with notable growth in multiple myeloma therapies and expectations for FDA approvals for RYBREVANT Faspro in head and neck cancer. - Immunology products like Tremfya and ICOTYDE are showing strong uptake, with Tremfya growing 68% in Q3. - The company is focused on enhancing its MedTech offerings, particularly with the launch of the OTTAVA robotic system and expanding its cardiovascular portfolio. - JNJ is committed to investing approximately $4.7 billion in R&D, representing 18.3% of sales.
5) Guidance and Outlook - JNJ raised its 2026 operational sales growth guidance to 6.7% to 7.1%, with adjusted EPS expected in the range of $10.95 to $11.05. - The company anticipates continued momentum in 2027, with a focus on internal investments rather than M&A to drive growth. - Upcoming data readouts and product approvals are expected to further enhance growth prospects.
Bottom line: JNJ's strong Q3 performance, driven by its Innovative Medicine segment and strategic focus on high-growth areas, positions the company well for sustained growth. Despite facing challenges in MedTech and litigation costs, the outlook for 2027 remains optimistic, with a clear path to achieving double-digit growth by the end of the decade.
Annual Reports, Presentations And IR Contacts
Go to the websiteJohnson & Johnson — Financial Overview, Stock Price, Market Cap
Johnson & Johnson is a company. Founded in 1886. As of October 19, 2026, the company's market capitalization is $615873685449 with a current stock price of $255.56.